Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

In this prospective, single-center, open-label study, baseline characteristics and the effects of 2-yr GH replacement were determined in 24 GHD adults above 65 yr of age and in 24 younger GHD patients (mean age, 37 yr; range, 27-46 yr).

All patients had adult onset disease, and both groups were comparable in terms of the number of pituitary hormonal deficiencies, gender, body mass index, and waist/hip ratio.

Duration of hypopituitarism was, however, longer in the elderly patients.

Why It Was Studied

The effects of GH replacement in elderly GH-deficient (GHD) adults are not well known.

Who Took Part

According to the abstract, 24 adults were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as open-label.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Biomarkers, Blood Pressure, Body Composition, Body Mass Index, Bone Density and Bone and Bones.

What This Means in Plain Language

The paper is an open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.